CHEST pulmonary
Cure8 research brief
Why This Matters
People with Crohn’s or ulcerative colitis can rarely develop lung problems related to their disease or its treatments, and this review collates what is known about clinical features and therapies.
It underscores limited evidence and the need for clearer treatment guidelines, which affects patient care decisions when pulmonary complications occur.
Who Should Pay Attention
Adult patients with IBD who develop respiratory symptoms, gastroenterologists, pulmonologists, and clinicians managing IBD; researchers studying extraintestinal manifestations or the gut–lung axis.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This review summarizes pulmonary (lung) complications that can occur with Crohn’s disease and ulcerative colitis and discusses treatment strategies described in case reports and series.
It highlights a range of lung involvement — airways, parenchyma, pleura, vasculature, fistulae, and drug-induced lung injury — and notes most reported cases have responded to corticosteroids.
The review also covers use of immunomodulators and biologic therapies in refractory or specific situations and includes clinical, radiologic, and pathologic correlations.
The paper emphasizes that evidence is limited: most data come from case reports and small series rather than controlled trials, so clear guidance on steroid dosing/duration and on management of steroid-refractory disease is lacking. The review calls for further research to develop evidence-based diagnostic and management guidelines.
If you have IBD and new respiratory symptoms (cough, shortness of breath, chest pain) your care team may consider evaluation for extraintestinal pulmonary involvement; diagnosis usually uses imaging and sometimes lung biopsy, and treatment often involves corticosteroids with immunomodulatory or biologic escalation when needed.
This summary is based on the article abstract and provided full-text extraction (structured content depth: abstract); Cure8 has not independently verified underlying studies.
Keep In Mind
The article is a narrative review based largely on case reports and small series; it does not provide randomized trial evidence. Recommendations about steroid dosing, duration, and escalation strategies are not standardized and require clinical judgment and specialist input.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationCHEST pulmonary
AuthorsGhosh S, Deshwal H, Haraf R +6 more
Study typeReview, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedSep 9, 2023, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Pulmonary involvement in inflammatory bowel diseases: report of a national cohort over the past 5 years.
Lung inflammation can occur in children with IBD but is uncommon and may be hard to spot because symptoms can be vague or absent. Early recognition matters because imaging, bronchoscopy, and sometimes biopsy help...
Large Vessel Vasculitis in IBD Linked to Younger Onset, Distinct Clinical Features
This study suggests LVV can occur in people with IBD at younger ages and with distinct vascular findings, and it may arise even when gut disease is in remission. That matters for awareness, diagnosis, and coordination...
All-cause and cause-specific mortality in inflammatory bowel disease across the biologic era: a population-based matched cohort study.
This large, population-based study suggests people with Crohn's disease have modestly higher overall mortality than matched controls and higher deaths from specific causes (colorectal cancer, renal disease, non-Hodgkin...